Compare AVT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVT | MIRM |
|---|---|---|
| Founded | 1921 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.2B |
| IPO Year | 1994 | 2019 |
| Metric | AVT | MIRM |
|---|---|---|
| Price | $88.19 | $82.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $106.25 | ★ $153.07 |
| AVG Volume (30 Days) | ★ 1.1M | 732.8K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | 45.82 | ★ 74.59 |
| EPS | ★ 4.01 | N/A |
| Revenue | ★ $27,632,683,000.00 | $19,138,000.00 |
| Revenue This Year | $34.12 | $33.62 |
| Revenue Next Year | $5.84 | $17.72 |
| P/E Ratio | $23.17 | ★ N/A |
| Revenue Growth | ★ 24.47 | N/A |
| 52 Week Low | $44.25 | $63.23 |
| 52 Week High | $108.63 | $130.00 |
| Indicator | AVT | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 37.23 | 43.78 |
| Support Level | $82.88 | $78.07 |
| Resistance Level | $89.21 | $88.31 |
| Average True Range (ATR) | 3.19 | 3.94 |
| MACD | -1.53 | 0.72 |
| Stochastic Oscillator | 11.25 | 50.24 |
Avnet Inc is an electronic component technology distributor and solutions provider serving customers across the Americas, EMEA, and Asia. It works with electronic component manufacturers in every electronic component segment and serves startups, mid-sized businesses, enterprise-level original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, and original design manufacturers (ODMs). Its segments are Electronic Components (EC) and Farnell, with EC generating maximum revenue. The EC operating group mainly supports high- and medium-volume customers and markets, and sells and distributes semiconductors, IP&E components (interconnect, passive, and electromechanical components), and other integrated and embedded components.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.